Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07458542) titled 'Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia' on Feb. 25.
Study Type: Observational
Primary Sponsor: Bristol-Myers Squibb
Condition:
Acute Myeloid Leukemia (AML)
Intervention:
Drug: Azacitidine
Recruitment Status: Not recruiting
Date of First Enrollment: December 9, 2025
Target Sample Size: 44
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07458542
Published by HT Digital Content Services with permission from Health Daily Digest....